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Objectives: The mortality of ruptured infrarenal
abdominal aortic aneurysms (rAAA) is as high as 70%.
Loss of consciousness and systolic blood pressure on
presentation of less than 80 mmHg are the most important
predictors of mortality after emergent open repair (OR).
Endovascular repair of abdominal aortic aneurysm
(EVAR) has reduced short-term operative mortality and
morbidity for elective abdominal aortic aneurysm repair
and many have advocated for wider application of EVAR
for rAAA. The objective of this study is to compare our
experience with OR and EVAR management of rAAA.
Methods: A retrospective review of all rAAA present-
ing to our institution from 2000 to 2011 was performed.
Patients were grouped based on the surgical approach
taken (OR or EVAR). Demographics,co-morbidities,
mortality and morbidity rates were compared.Statistical
analyses were conducted with Stata, version 12.
Results: 145 patients presented with rAAA over the
study period. 22% of patients underwent EVAR, 64%
underwent OR and 14% declined repair. A preoperative
computed tomography scan was available in 99 patients.
Only one patient (0.69%) required conversion to OR
from EVAR.There was no statistical difference in 30-day
(EVAR, 25%; OR, 40%; P ¼ .12) and 1-year (EVAR,
31.25%; OR, 45.74%; P ¼ .5)mortality rates.Morbidity
was 78% in the EVAR and 75% in OR group. Respiratory
failure and abdominal compartment syndrome were the
major complications in the patients undergoing EVAR,
while respiratory and renal failure were most common in
the patients undergoing OR.
Conclusions: In contrast to recently published series,
this review shows no difference in clinical outcome
between EVAR and OR in the treatment of rAAA. The
comorbidities and the clinical status of the patient upon
arrival to the hospital remain the most important prog-
nostic predictors of morbidity and mortality. Until
randomized trial data are available, these results lead us
to pursue EVAR for rAAA in stable patients with favorable
anatomy rather than a more universal approach.
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Objectives: Vascular related complications negatively
impact nearly 1/3 of patients undergoing transcatheter
aortic valve replacement (TAVR). This study evaluates
the utilization of vascular adjunctive procedures and bail-
outs during TAVR in the “real-world scenarios.”
Methods: In 2012, we evaluated aortoiliac morphology
and outcomes of 103 consecutive patients that underwent
TAVR (n¼ 53; 51%) with the structural heart team inclusive
of cardiologists and cardiac & vascular surgeons, and TEVAR
(n ¼ 50; 49%). Patients were evaluated on an intent-to-treat
basis, and data on all adjunctive vascular procedures & bail-
outs was prospectively collected.
Results: The 30-day mortality of TAVR (4%) and
TEVAR (2%) was comparable. TAVR patents were older
(mean age, 80 yrs vs 70 yrs; P < .01), and had a higher inci-
dence of aortoiliac signiﬁcant circumferential calciﬁcations
(14% vs 6%). Hostile aortoiliac access that would have
excluded patients form TAVR was noted in 21 (42%)
patients. Compared to TEVAR, TAVR patients had a signif-
icantly higher incidence of vascular complications (18% vs
6%; P < .05), and the need for secondary vascular proce-
dures (48% vs 2%; P < .01) including misplaced aortic valve
retrieval (n¼ 3; 6%), aortoiliac interventions (n¼ 10; 20%),
and iliofemoral reconstructions (n ¼ 11, 22%).
Conclusions: When compared to TEVAR, TAVR
patients are older, have more complex aortoiliac access,
have a higher incidence of vascular complications, and
have a greater need for adjunctive secondary vascular proce-
dures. Regardless, vascular surgeon’s primary involvement
limits the vascular morbidity and mortality, and expands
TAVR indications for use to over 40% of inoperable and
high-risk patients that are currently denied treatment.
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Objectives: To analyze predictors and long-term
consequence of type II endoleak in a large series of elective
EVAR.
Methods: Baseline characteristics, operative and
follow-up data of consecutive patients undergoing
EVAR were prospectively collected. Patients who devel-
oped type II endoleak according to CT scan and those
without were compared for baseline characteristic, mor-
tality, reintervention, conversion and aneurysm growth
after repair.
Results: 1412 consecutive patients (91.4% males;
mean age, 72.9) underwent elective EVAR in 1997-2012
and were subsequently followed for a mean of 54 6 42
months. 218 developed type II endoleak. Multivariate
analysis failed to identify type II endoleak signiﬁcant inde-
pendent predictors with the exception of age (P ¼ .026;
OR, 1.023) and neck thrombus (P ¼ .011; OR, .303).
Rates of type II endoleak were comparable regardless the
type of device but there was a tendency for lower rate
with most recent generation devices. Freedom from aneu-
rysm sac growth >5 mm (95.2% vs 42.4%; P < .001) rein-
tervention (92.3% vs 49.6%; P < .001) or conversion
(98.5% vs 80%; P < .001) at 120 months was higher in
patients without type II endoleak.
Fifty-two patients with type II endoleak underwent
reintervention. At 60 months, rates of persisting type II
endoleak were similar among patients with and without
reinterventions (49.8% vs 45.6%). There were no signiﬁ-
cant difference in persisting aneurysm growth >5 mm in
type II endoleak patients after reintervention and those
who remained untreated (57.1% vs 42.6%).
Cox regression identiﬁed type II endoleak as indepen-
dent predictor of aneurysm growth along with age and
cardiac disease.
There were four aneurysm ruptures during follow-up
in patients with type II endoleak. Late aneurysm related
mortality at 120 months was 3.8% vs 2.1% for patients
with and without type II endoleak.
Conclusions: Type II endoleak is a common marker
of EVAR failure reﬂecting multiple meanings. Occurrence
and consequences are challenging to be predicted and
treatment with reinterventions often results in failure.
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Objectives: Aortic infections, even with treatment,
have a high mortality and risk of recurrent infection and
limb loss. CAA has been proposed for in-line reconstruc-
tion to improve outcomes in this high-risk population.
Methods: A multi-center study using a standardized
database was performed at 14 of the highest volume insti-
tutions who used CAA for aortic infection.
Results: Two hundred and twenty patients (mean age
¼ 65; M:F ¼ 1.6/1) were treated since 2000 with 283
CAAs for prosthetic graft infection (59%), primary aortic
infection (17%), enteric ﬁstula/erosion (16%), mycotic
aneurysm (4%), and other (4%). Intra-op cultures indicated
infection in 66%, most frequently polymicrobial. Distal
anastomosis was to the femoral artery, iliac, then distal
aorta. 30-day mortality was 9% and procedure related
major complications occurred in 24%, including persistent
sepsis (n ¼ 17), graft thrombosis (n ¼ 9), graft/stump
rupture (n ¼ 8), recurrent CAA/aortic infection (n ¼ 8),
pseudoaneurysm (n ¼ 6), recurrence of AE ﬁstula (n ¼
4), and compartment syndrome (n ¼ 1). Hospital LOS
was 24 days. Ten (5%) required allograft explant; 2 devel-
oped CAA aneurysm requiring resection at 23 and 40 mo.
Primary graft patency and freedom from limb loss were
93% and 97%, respectively, at 5 yr. Patient survival was
75% at 1 yr and 51% at 5 yr.
Conclusions: This largest study indicates that CAA
allows in-line reconstruction of aortic infection with lower
